ALG1L6P

Across TCGA pan-cancer cohorts, ALG1L6P RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of ALG1L6P’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where ALG1L6P RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ALG1L6P is over-expressed in tumor, although a few such as BRCA and KICH show the opposite, repressed pattern.

THCA, LIHC, and BRCA are the cancer types where ALG1L6P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ALG1L6P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	III,IV	+0.901	<.001	9	view →
LIHC	Male	All	+0.701	<.001	8	view →
BRCA	Female	II,III,IV	−0.432	<.001	6	view →
COAD	Male	All	+0.521	.004	4	view →
CHOL	All	All	+1.788	<.001	3	view →
KIRP	Female	All	+0.994	<.001	3	view →
READ	All	III,IV	+0.950	.033	2	view →
KICH	Female	All	−0.638	.005	2	view →
UCEC	All	All	−0.589	.001	2	view →
LUAD	All	All	+0.288	.009	2	view →
KIRC	Male	All	−0.264	.036	2	view →
LUSC	All	All	−0.285	.023	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

ALG1L6P–THCA

Open the THCA breakdown →